Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Vascular Medicine
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Anthony, S.
Right arrow Articles by Vallance, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anthony, S.
Right arrow Articles by Vallance, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Endogenous production of nitric oxide synthase inhibitors

Shelagh Anthony

Centre for Clinical Pharmacology, The British Heart Foundation Laboratories, University College London, UK

James Leiper

Centre for Clinical Pharmacology, The British Heart Foundation Laboratories, University College London, UK, james.leiper{at}ucl.ac.uk

Patrick Vallance

Centre for Clinical Pharmacology, The British Heart Foundation Laboratories, University College London, UK

Numerous reports have indicated that the plasma concentration of endogenously produced inhibitors of nitric oxide synthase are elevated in human disease states. In this review we discuss recent advances in our understanding of the enzymes responsible for the synthesis of these inhibitors.

Key Words: asymmetric methylarginine • dimethylarginine dimethylaminohydrolase • nitric oxide synthase • protein-arginine methyltransferase

Vascular Medicine, Vol. 10, No. 2 suppl, S3-S9 (2005)
DOI: 10.1191/1358863x05vm595oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann Clin BiochemHome page
S. Blackwell
The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine
Ann Clin Biochem, January 1, 2010; 47(1): 17 - 28.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. Turiel, F. Atzeni, L. Tomasoni, S. de Portu, L. Delfino, B. D. Bodini, M. Longhi, S. Sitia, M. Bianchi, P. Ferrario, et al.
Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients
Rheumatology, July 1, 2009; 48(7): 834 - 839.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
D. Wang, P. S. Gill, T. Chabrashvili, M. L. Onozato, J. Raggio, M. Mendonca, K. Dennehy, M. Li, P. Modlinger, J. Leiper, et al.
Isoform-Specific Regulation by NG,NG-Dimethylarginine Dimethylaminohydrolase of Rat Serum Asymmetric Dimethylarginine and Vascular Endothelium-Derived Relaxing Factor/NO
Circ. Res., September 14, 2007; 101(6): 627 - 635.
[Abstract] [Full Text] [PDF]